Therapy Detail

Therapy Name Durvalumab
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK rearrange non-small cell lung carcinoma no benefit Durvalumab Clinical Study Actionable In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). 27225694
ALK rearrange non-small cell lung carcinoma no benefit Durvalumab Guideline Actionable Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). detail...
Unknown unknown glioblastoma multiforme not applicable Durvalumab Phase II Actionable In a Phase II trial, Imfinzi (durvalumab) treatment resulted in partial response in 16.7% (5/30), stable disease in 43.3% (13/30), and an estimated 6 month progression free survival of 20.0% in patients with Bevacizumab-naive, recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi18.). detail...
Unknown unknown transitional cell carcinoma not applicable Durvalumab FDA approved Actionable In a Phase I/II trial that supported FDA approval, treatment with Imfinzi (durvalumab) was well tolerated and resulted in an overall response rate of 17.8% (34/191; 7 complete responses), median progression-free survival of 1.5 months, and median overall survival of 18.2 months in patients with advanced urothelial cancer (PMID: 28817753; NCT01693562). detail... 28817753
Unknown unknown non-small cell lung carcinoma not applicable Durvalumab Phase III Actionable In a Phase III trial (PACIFIC) that supported FDA approval, Imfinzi (durvalumab) treatment resulted significantly improved median progression-free survival (PFS) (16.8 vs 5.6 months, HR=0.52, p<0.001), and superior 12-month PFS rate (55.9% vs 35,3%), 18-month PFS rate (44.2% vs 27.0%), response rate (28.4% vs 16%), and median time to death or distant metastasis (23.2 vs 14.6 months) compared to placebo in patients with unresectable, non-small cell lung cancer (PMID: 28885881; NCT02125461). 28885881
Unknown unknown alveolar soft part sarcoma not applicable Durvalumab Clinical Study Actionable In a clinical case study, a patient with alveolar soft part sarcoma had a 58% reduction of target lesions and a response lasting 12 months when treated with Imfinzi (durvalumab), and the tumor was shown retrospectively to have a mismatch repair defect signature, poor immune infiltration, and 0% tumoral PD-L1 positivity (PMID: 30018044; NCT01693562). 30018044
Clinical Trial Phase Therapies Title Recruitment Status
NCT02291055 Phase Ib/II Durvalumab ADXS11-001 Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer Suspended
NCT02886065 Phase I Durvalumab PVX-410 + MEDI4736 PVX-410 + MEDI4736 + lenalidomide A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma Recruiting
NCT02340975 Phase Ib/II Durvalumab Tremelimumab A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Active, not recruiting
NCT02352948 Phase III Durvalumab Erlotinib + Gemcitabine + Vinorelbine Durvalumab + Tremelimumab Tremelimumab A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Active, not recruiting
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Carboplatin + Pemetrexed Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab Carboplatin + nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Recruiting
NCT03084471 Phase III Durvalumab + Tremelimumab Durvalumab An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) Recruiting
NCT03840902 Phase II Paclitaxel + Carboplatin M7824 Cisplatin + Pembrolizumab Cisplatin + Etoposide Durvalumab Cisplatin + Etoposide + M7824 Carboplatin + M7824 + Paclitaxel Cisplatin + M7824 + Pemetrexed M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Not yet recruiting
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting
NCT03283943 Phase I Durvalumab PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. Recruiting
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Recruiting
NCT02592551 Phase II Durvalumab + Tremelimumab Durvalumab MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Recruiting
NCT02551159 Phase III Cisplatin Durvalumab Cetuximab + Carboplatin + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Active, not recruiting
NCT02273375 Phase III Durvalumab Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Recruiting
NCT02793466 Phase I Durvalumab Durvalumab in Pediatric and Adolescent Patients Recruiting
NCT03635164 Phase I Durvalumab Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma Recruiting
NCT02087423 Phase II Durvalumab A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) Active, not recruiting
NCT03693300 Phase II Durvalumab A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Not yet recruiting
NCT02369874 Phase III Durvalumab + Tremelimumab Durvalumab Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Active, not recruiting
NCT02454933 Phase III Osimertinib Durvalumab Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours Active, not recruiting
NCT03258554 Phase II Cetuximab Durvalumab Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin Suspended
NCT02966587 Phase II Durvalumab Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Withdrawn
NCT03148327 Phase Ib/II Durvalumab Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy Recruiting
NCT02125461 Phase III Durvalumab A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) Active, not recruiting
NCT02319044 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT03277482 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Recruiting
NCT03235869 Phase I Durvalumab Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma Withdrawn
NCT02088112 Phase I Gefitinib Durvalumab MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC) Active, not recruiting
NCT03102047 Phase II Durvalumab Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer Recruiting
NCT03245541 Phase Ib/II Durvalumab Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) Suspended
NCT03015129 Phase II Durvalumab Durvalumab + Tremelimumab A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Recruiting
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Recruiting
NCT02527434 Phase II Durvalumab + Tremelimumab Durvalumab Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated
NCT01693562 Phase Ib/II Durvalumab A Phase 1/2 Study to Evaluate MEDI4736 Active, not recruiting
NCT02179671 Phase II Selumetinib + Docetaxel Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
NCT03703297 Phase III Durvalumab Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Recruiting
NCT03003962 Phase III Durvalumab Gemcitabine + Cisplatin Carboplatin + Gemcitabine Carboplatin + Pemetrexed Cisplatin + Pemetrexed Paclitaxel + Carboplatin Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer Active, not recruiting
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed
NCT02207530 Phase II Durvalumab Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. Active, not recruiting
NCT03830866 Phase III Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) Not yet recruiting
NCT02301130 Phase I Mogamulizumab Durvalumab Tremelimumab Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors Completed
NCT03199040 Phase I Durvalumab Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Recruiting
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Recruiting
NCT03589547 Phase II Durvalumab Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Not yet recruiting
NCT02904954 Phase II Durvalumab Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer Recruiting
NCT02205333 Phase Ib/II Rituximab MEDI6469 Tremelimumab Durvalumab A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies Terminated
NCT03011814 Phase Ib/II Durvalumab lenalidomide + MEDI4736 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Recruiting
NCT03618134 Phase Ib/II Durvalumab Durvalumab + Tremelimumab Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Recruiting
NCT02154490 Phase II Docetaxel Palbociclib Durvalumab AZD4547 Taselisib Erlotinib AMG102 Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer Recruiting
NCT02499328 Phase Ib/II AZD9150 + Durvalumab AZD5069 + MEDI4736 Durvalumab AZD9150 Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Recruiting
NCT03150836 Phase II Durvalumab Durvalumab + Tremelimumab Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer Withdrawn
NCT02788773 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03206073 Phase Ib/II Durvalumab + Tremelimumab Durvalumab A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Recruiting
NCT02453282 Phase III Durvalumab Gemcitabine + Cisplatin Paclitaxel + Carboplatin Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Active, not recruiting
NCT02546661 Phase I AZD4547 Durvalumab Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer Recruiting
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Recruiting
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Recruiting
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Recruiting
NCT02227667 Phase II Durvalumab Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer Active, not recruiting
NCT03802747 Phase I Durvalumab + Tremelimumab Durvalumab Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Not yet recruiting
NCT03196401 Phase I Durvalumab A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma Withdrawn
NCT02891161 Phase Ib/II Durvalumab Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Recruiting
NCT03215095 Phase I Durvalumab RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers Recruiting
NCT02503774 Phase I Durvalumab Oleclumab MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Recruiting
NCT02535078 Phase Ib/II Durvalumab IMCgp100 Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Active, not recruiting
NCT03410615 Phase II Durvalumab + Tremelimumab Cisplatin Durvalumab Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC Recruiting
NCT03818776 Phase I Durvalumab Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC Not yet recruiting
NCT02899195 Phase II Cisplatin + Durvalumab + Pemetrexed Durvalumab Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) Active, not recruiting
NCT03317158 Phase Ib/II Durvalumab BCG solution + Durvalumab ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Recruiting
NCT03038477 Phase II Durvalumab A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection Suspended
NCT03601455 Phase II Durvalumab + Tremelimumab Durvalumab Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer Not yet recruiting
NCT03833154 Phase III Durvalumab Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) Not yet recruiting
NCT03618654 Phase I Durvalumab + Metformin Durvalumab Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Recruiting
NCT02879617 Phase II Durvalumab A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Recruiting
NCT03775486 Phase II Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) Recruiting
NCT03459846 Phase II Durvalumab + Olaparib Durvalumab A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) Recruiting
NCT03794544 Phase II Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + IPH2201 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Not yet recruiting
NCT02558894 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed
NCT02733042 Phase Ib/II Rituximab lenalidomide + MEDI4736 + Rituximab Bendamustine + MEDI4736 + Rituximab Ibrutinib + MEDI4736 Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Active, not recruiting
NCT03144778 Phase I Durvalumab Durvalumab + Tremelimumab Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO) Recruiting
NCT03778957 Phase III Durvalumab Bevacizumab + MEDI4736 A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) Recruiting
NCT02827838 Phase I Durvalumab Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Recruiting
NCT02336165 Phase II Durvalumab Bevacizumab + MEDI4736 Phase 2 Study of MEDI4736 in Patients With Glioblastoma Active, not recruiting
NCT03490760 Phase II Durvalumab Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas Recruiting
NCT02549651 Phase I Durvalumab + Tremelimumab Durvalumab AZD9150 + Durvalumab MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) Active, not recruiting
NCT02616640 Phase I Pomalidomide Dexamethasone Durvalumab A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Active, not recruiting
NCT03007407 Phase II Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Recruiting
NCT03822351 Phase II Durvalumab Durvalumab + IPH2201 Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Recruiting
NCT01993810 Phase III Carboplatin + Pemetrexed Durvalumab Cisplatin + Etoposide Paclitaxel + Carboplatin Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Recruiting
NCT02311361 Phase I Durvalumab Tremelimumab Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Recruiting
NCT02639065 Phase II Durvalumab A Study of Durvalumab (MEDI4736) in Esophageal Cancer Active, not recruiting
NCT02901548 Phase II Durvalumab Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder Recruiting
NCT02221960 Phase I Durvalumab MEDI6383 A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Active, not recruiting
NCT03773666 Phase I Durvalumab + Oleclumab Durvalumab A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Not yet recruiting